In 796 patients with uncontrolled or resistant hypertension, baxdrostat 1 mg or 2 mg added to background therapy lowered seated systolic BP at 12 weeks vs placebo (placebo-corrected −8.7 and −9.8 mm Hg). Potassium >6.0 mmol/L: 2.3% and 3.0% vs 0.4%.
RCTn = 796
Flack et al. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension